FCGR3A: Low affinity immunoglobulin gamma Fc region receptor III-A
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG).
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on FCGR3A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Bemarituzumab | Phase 3 | Chia Tai Tianqing Pharmaceutical | Antibody | Binding agentLow affinity immunoglobulin gamma Fc region receptor III-A binding agent | 4 |
| Imgatuzumab | Phase 2 | Roche | Antibody | Cross-linking agentLow affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent | 0 |
- Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity0.69
- Cutaneous leishmaniasis0.58
- Gastric cancer0.34
- Gastric neoplasm0.33
- Takayasu arteritis0.21
- Neoplasm0.13
- Rheumatoid arthritis0.12
- COVID-190.11
- Gastric adenocarcinoma0.10
- Cancer0.10
- Systemic lupus erythematosus0.10
- Posterior cortical atrophy0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3856162, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08637, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets